In the present study, FoxC2 siRNA suppressed β1-integrin expression and EP1R-mediated cell migration in NSCLC cells; the EP1 agonist improved FoxC2 expression; while Rottlerin suppressed EP1R-mediated FoxC2 expression significantly; ChIP assay identified that EP1 agonist treatment increased FoxC2 binding to β1-integrin promoter. This evidence concerns the gene FOXC2 and non-small cell lung carcinoma.